ストックスクリーナーアプリを入手
2.95
30.09%
-1.27
Alaunos Therapeutics Inc (TCRT) 最新ニュース
Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Down 12.5% in March - Defense World
Alaunos Therapeutics (NASDAQ:TCRT) Shares Down 6.5% – Here’s What Happened - Defense World
Lantheus acquires radiopharma CDMO Evergreen for up to $1bn - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Up 4% – Should You Buy? - Defense World
Light Horse emerges with $62m and Novartis partnership worth up to $1bn - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Down 0.5% – Time to Sell? - Defense World
TCRT stock touches 52-week low at $1.92 amid market challenges - Investing.com
Novartis acquires Kate Therapeutics to advance gene therapies - Pharmaceutical Technology
Alaunos Therapeutics Inc (TCRT) Quarterly 10-Q Report - Quartzy
Ziopharm: Q3 Earnings Snapshot - The Washington Post
TCRT Stock Touches 52-Week Low at $1.96 Amid Market Challenges - Investing.com Nigeria
TCRT stock touches 52-week low at $2.06 amid market challenges - Investing.com
Intracranial Therapeutic Market Rewriting its Growth Cycle |Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics, – IndiaPolitics.com - IndiaPolitics.com
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen - Fierce Biotech
Alaunos Therapeutics ends key agreement and updates on financial condition By Investing.com - Investing.com Australia
Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy - Yahoo Finance
Precigen reclaims rights after terminating license agreement - Investing.com India
Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch
Alaunos Therapeutics ends key agreement and updates on financial condition - Investing.com
Genentech buys Regor’s CDK inhibitors in $850m deal - Clinical Trials Arena
AskBio and Belief BioMed partner to advance gene therapies - Pharmaceutical Technology
Gene Switch / Molecular Switch Market Set to Reach USD 1.44 Billion by 2031 with 9.9% CAGR - WhaTech
Gilead and Genesis partner to create novel therapies using AI - Pharmaceutical Technology
Navigator gains $100m in Series A funding for antibody therapeutics - Pharmaceutical Technology
VION Biosciences acquires Echelon Biosciences - Pharmaceutical Technology
Eli Lilly inaugurates R&D facility in Boston, US - Pharmaceutical Technology
Genentech and Sangamo to develop neurodegenerative disease therapies - Pharmaceutical Technology
Alaunos Therapeutics announces 1-for-10 reverse stock split - Investing.com
XyloCor taps SmartWise’s infusion device for gene therapy administration - Clinical Trials Arena
Turn Bio and HanAll to develop therapies for age-related conditions - Pharmaceutical Technology
Avenzo Therapeutics secures $150m to bolster oncology pipeline - Pharmaceutical Technology
Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn - Pharmaceutical Technology
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Markets Insider
Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split - TipRanks
TScan Therapeutics Appoints Jason A. Amello as Chief Financial Officer - citybiz
Kyowa Kirin acquires Orchard Therapeutics for $477.6m - Pharmaceutical Technology
NAYA buys gene therapy company Florida Biotech for $20m - Clinical Trials Arena
Genentech signs nanoparticle deal worth up to $644m with GenEdit - Pharmaceutical Technology
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
Avistone raises $140m to support drug research and development - Pharmaceutical Technology
BridGene and Galapagos partner for oncology drugs discovery - Pharmaceutical Technology
Novartis allies with Voyager to develop gene therapies in $1.3bn deal - Pharmaceutical Technology
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today? - MSN
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Markets Insider
Syncona to buy biotechnology company Freeline Therapeutics - Pharmaceutical Technology
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives - Yahoo Finance
Ascidian Therapeutics raises $40m to advance drug development - Pharmaceutical Technology
AstraZeneca and Cellectis partner to advance cell and gene therapies - Pharmaceutical Technology
How gene therapies can transform sickle cell disease treatment - Pharmaceutical Technology
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65% - Nasdaq
Houston biotech winds down sole clinical-stage trial, cuts 60% of staff - Fierce Biotech
Neoleukin to merge with Neurogene for $200m in cash reserves - Pharmaceutical Technology
15 Biotech Stocks Wall Street Analysts Say Are Too Cheap - Barron's
Hopewell Therapeutics raises funds for genomic medicines development - Pharmaceutical Technology
Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting - StockTitan
The past five years for Alaunos Therapeutics (NASDAQ:TCRT) investors has not been profitable - Yahoo Finance
Precigen Regains Exclusive Rights To Proven CAR-T Targets, CD19/BCMA - Contract Pharma
3.01%
大文字化:
|
ボリューム (24 時間):